Business Context and Reporting Period
This Form 8-K was filed by Kiora Pharmaceuticals, Inc. (KPRX) on August 23, 2022. The report addresses the Company's status regarding continued listing on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes and Listing Status
- Initial Notice: On February 23, 2022, the Company received notice from Nasdaq of non-compliance with the minimum bid price requirement (Rule 5550(a)(2)), which requires a closing bid price of at least $1.00 for 10 consecutive business days.
- Extension Granted: On August 23, 2022, Nasdaq granted an additional 180-day compliance period, extending the deadline to February 20, 2023.
- Conditions for Extension: The extension was granted because the Company met all other initial listing requirements, including the market value of publicly held shares, and submitted a plan to cure the deficiency.
Outlook, Management Commentary, and Risks
- Management Plan: The Company intends to consider available options to regain compliance, including the implementation of a reverse stock split if necessary.
- Delisting Risk: If the Company fails to regain compliance by February 20, 2023, Nasdaq will determine to delist the common stock.
- Appeal Process: In the event of a delisting determination, the Company may appeal to a hearings panel. The stock would remain listed pending the panel's decision, though there is no assurance of a successful appeal.
Investor Verification Checklist
- Verify the current trading price of KPRX to assess proximity to the $1.00 minimum bid price requirement.
- Monitor future filings for announcements regarding a reverse stock split or other capital structure changes.
- Confirm the Company's progress toward the February 20, 2023, compliance deadline.
- Review the Company's cash position in other filings to ensure sufficient liquidity to execute a reverse stock split if required.